MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma

Blood

Volumn 113, Issue 26, 2009, Pages 6669-6680

  Roccaro, Aldo M ^a,b,c   Sacco, Antonio ^a   Thompson, Brian ^a   Leleu, Xavier ^a   Azab, Abdel Kareem ^a   Azab, Feda ^a   Runnels, Judith ^a   Jia, Xiaoying ^a   Ngo, Hai T ^a   Melhem, Molly R ^a   Lin, Charles P ^a   Ribatti, Domenico ^c   Rollins, Barrett J ^a   Witzig, Thomas E ^d   Anderson, Kenneth C ^a   Ghobrial, Irene M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN S6; SYNDECAN 1; AKT3 PROTEIN, HUMAN; ANGIOGENESIS INHIBITOR; MIRN15 MICRORNA, HUMAN; MIRN16 MICRORNA, HUMAN; PROTEIN KINASE INHIBITOR; RNA; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BIOSYNTHESIS; CANCER STEM CELL; CELL ADHESION; CELL DIVISION; COCULTURE; CYTOLOGY; DRUG ANTAGONISM; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; PROGNOSIS; STATISTICS; STROMA CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL ADHESION; CELL DIVISION; CLINICAL TRIALS, PHASE II AS TOPIC; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, SCID; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; NF-KAPPA B; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6; RNA, NEOPLASM; STROMAL CELLS;

EID: 69249225706     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-01-198408     Document Type: Article

References (54)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860-1873.
2. Jemal A, Murray T, Ward E, et al. CA Cancer J Clin. 2005;55:10-30.
3. Richardson PG, Barlogie B, Berenson J, et al.A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617. (Pubitemid 36741588)
4. Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002;99:3735-3741. (Pubitemid 34534545)
5. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64:1546-1558. (Pubitemid 38235629)
6. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843-854. (Pubitemid 24014542)
7. Xie X, Lu J, Kulbokas EJ, et al. Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals. Nature. 2005;434:338-345.
8. Bentwich I, Avniel A, Karov Y, et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet. 2005;37:766-770. (Pubitemid 41754896)
9. He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004; 5:522-531. (Pubitemid 38868508)
10. Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A. 2004;101:11755-11760. (Pubitemid 39095368)
11. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65:7065-7070. (Pubitemid 41161233)
12. Marcucci G, Radmacher MD, Maharry K, et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358: 1919-1928. (Pubitemid 351620112)
13. Pichiorri F, Suh SS, Ladetto M, et al. MicroRNAs regulate critical genes associated with multiple meyloma pathogenesis. Proc Natl Acad Sci U S A. 2008;105:12885-12890.
14. Fonseca R, Blood E, Rue M, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003;101:4569-4575. (Pubitemid 36857829)
15. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412-3420.
16. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101:1530-1534. (Pubitemid 36182530)
17. Roccaro AM, Hideshima T, Raje N, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 2006;66:184-191. (Pubitemid 43166024)
18. Alsayed Y, Ngo H, Runnels J, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)- dependent migration and homing in multiple myeloma. Blood. 2007;109:2708-2717. (Pubitemid 46482062)
19. Leleu X, Jia X, Runnels J, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2007;110:4417-4426.
20. Ahn KS, Sethi G, Aggarwal BB. Embelin, an inhibitor of X chromosome-linked inhibitor-ofapoptosis protein, blocks nuclear factor-kappaB (NF-kappaB) signaling pathway leading to suppression of NF-kappaB- regulated antiapoptotic and metastatic gene products. Mol Pharmacol. 2007;71:209-219. (Pubitemid 46020991)
21. Felli N, Fontana L, Pelosi E, et al. MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A. 2005;102:18081-18086. (Pubitemid 41798505)
22. Conaco C, OttoS, Han JJ, Mandel G. Reciprocal actions of REST and a microRNA promote neuronal identity. Proc Natl Acad Sci U S A. 2006;103: 2422-2427. (Pubitemid 43271685)
23. Nottrott S, Simard MJ, Richter JD. Human let-7a miRNAblocks protein production on actively translating polyribosomes. Nature. 2006;13:1108-1114. (Pubitemid 44885922)
24. Roccaro AM, Sacco A, Chen C, et al. microRNA expression in the biology, prognosis and therapy of Waldenstrom macroglobulinemia. Blood. 2009; 113:4391-4402.
25. Chen C, Ridzon DA, Broomer AJ, et al. Real-time quantification of microRNAs by stem-loop RTPCR. Nucleic Acids Res. 2005;33:e179. (Pubitemid 41806407)
26. Livak KJ, Scmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;24:402-408. (Pubitemid 34164012)
27. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002;99:14374-14379. (Pubitemid 35257679)
28. Chauhan D, Neri P, Velankar M, et al. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood. 2007;109:1220-1227. (Pubitemid 46220671)
29. Podar K, Tonon G, Sattler M, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A. 2006;103:19478-19483. (Pubitemid 46026056)
30. Sipkins DA,Wei X,Wu JW, et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature. 2005;435:969-973.
31. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell. 2003;115:787-798.
32. Krek A, Grun D, Poy MN, et al. Combinatorial microRNA target predictions. Nat Genet. 2005; 37:495-500.
33. Lee YJ, Lee HJ, Lee JS, et al.Anovel function for HSF1-induced mitotic exit failure and genomic instability through direct interaction between HSF1 and Cdc20. Oncogene. 2008;27:2999-3009.
34. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005;102:13944-13949. (Pubitemid 41377683)
35. Stahl JM, Sharma A, Cheung M, et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004;64:7002-7010. (Pubitemid 39331010)
36. Sharma A, Sharma AK, Madhunapantula SV, et al. Targeting Akt3 Signaling in malignant melanoma using isoselenocyanates. Clin Cancer Res. 2009;15:1674-1685.
37. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12:131-144.
38. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12:115-130. (Pubitemid 47199123)
39. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639-16647. (Pubitemid 34967682)
40. Leleu X, Eeckhoute J, Jia X, et al. Targeting NFkappaB in Waldenstrom macroglobulinemia. Blood. 2008;111:5068-5077.
41. Ishitani T, Takaesu G, Ninomiya-Tsuji J, Shibuya H, Gaynor RB, Matsumoto K. Role of the TAB2- related protein TAB3 in IL-1 and TNF signaling. EMBO J. 2003;22:6277-6288. (Pubitemid 37522585)
42. Kanayama A, Seth RB, Sun L, et al. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol Cell. 2004;15: 535-548. (Pubitemid 39141781)
43. Jin G, Klika A, Callahan M, et al. Identification of a human NF-kappaB-activating protein, TAB3. Proc Natl Acad Sci U S A. 2004;101:2028-2033.
44. Ria R, Vacca A, Russo F, et al. A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thromb Haemost. 2004;92:1438-1445. (Pubitemid 39642557)
45. Vacca A, Ria R, Ribatti D, et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica. 2003;88:176-185. (Pubitemid 37101495)
46. Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006;42: 1564-1573.
47. Yoeli-Lerner M, Toker A. Akt/PKB signaling in cancer: a function in cell motility and invasion. Cell Cycle. 2006;5:603-605.
48. Weniger MA, Melzner I, Menz CK, et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene. 2006;25:2679-2684.
49. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175-187.
50. Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64:1546-1558. (Pubitemid 38235629)
51. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99:15524-15529. (Pubitemid 35403967)
52. Bonci D, Coppola V, Musumeci M, et al. The miR- 15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008;14:1271-1277.
53. Chen RW, Bemis LT, Amato CM, et al. Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood. 2008;112:822-829.
54. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells up-regulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15:1950-1961.